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An  outbreak  of  extended-spectrum  β-lactamase–
producing Escherichia coli in a neonatal care unit began 
with  transmission  from  a  mother  to  her  newborn  twins 
during vaginal delivery. Subsequently, infection spread by 
healthcare worker contact with other neonates; a healthcare 
worker also was infected. Knowledge about transmission 
may improve infection control measures.
G
ram-negative Enterobacteriaceae expressing extend-
ed-spectrum β-lactamase (ESBL) are among the most 
multidrug-resistant pathogens in hospitals and are spread-
ing worldwide (1–3). Infections caused by ESBL–produc-
ing  organisms  have  resulted  in  poor  outcomes,  reduced 
rates  of  clinical  and  microbiological  responses,  longer 
hospital stays, and greater hospital expenses (4,5). Mul-
tiple outbreaks of ESBL-producing Enterobacteriaceae in 
intensive care units (ICUs) and increased rates of illness 
and death, especially in neonatal ICUs, have been reported 
(6–10). Physical contact is the most likely mode of trans-
mission. The gastrointestinal tract of colonized or infected 
patients is the most frequent reservoir. Several studies in-
dicate that transient carriage of bacteria on the hands of 
healthcare workers (HCWs) may lead to transmission to 
patients (7,11).
We report an outbreak of ESBL-producing Escheri-
chia coli (ESBL E. coli) in a neonatal intermediate care 
unit. Initial transmission was from a mother to her newborn 
twins and subsequently by physical contact of HCWs with 
other patients; an HCW also was infected.
The Study
The  Department  of  Obstetrics  and  Gynecology  of 
the University Hospital, Basel, Switzerland, has 94 beds; 
≈2,000 babies are delivered there each year. The neonatal 
unit includes 12 beds for healthy newborns and 9 beds for 
infants requiring intermediate care.
A  29-year-old  woman  with  dichorionic  twin  preg-
nancy  was  admitted  to  the  antenatal  care  unit  at  32 
weeks’ gestation because of spontaneous preterm rupture 
of membranes of the first twin. Her medical history was 
unremarkable. Screening results for gestational diabetes, 
as well as urinary controls and vaginal swabs for group 
B  Streptococcus,  were  negative.  After  confirmation  of 
preterm rupture of membranes by ultrasound and vaginal 
examination, therapy was initiated with amoxicillin/cla-
vulanic acid (3 × 2.2 g/d) for 10 days, tocolysis with bet-
amimetics (hexoprenaline) until 34 weeks’ gestation, and 
1 course of steroids for lung maturation (betamethasone   
2 × 12 mg with an interval of 24 h).
Five weeks later, the woman spontaneously delivered 
2 healthy boys (1,920 g, Apgar scores 9/10/10; and 2,045 
g, Apgar scores 8/9/9) under epidural analgesia with place-
ment of a urinary catheter. Two days after delivery, an   
asymptomatic urinary tract infection with ESBL E. coli 
was detected in the mother; it was treated with trimethop-
rim/sulfamethoxazole for 7 days. Follow-up urinalysis was 
negative for ESBL E. coli; however, rectal swab performed 
to document colonization was positive for ESBL E. coli. 
This pathogen persisted for >7 months after delivery, after 
which the patient was lost to follow-up.
Both twins were initially admitted to the neonatal in-
termediate care unit because of their prematurity. Six days 
after birth, screening rectal swabs confirmed colonization 
with ESBL E. coli in both neonates. The twins did not 
show clinical signs of infection and were discharged on 
their 20th day.
Screening of the 6 other neonates in the neonatal inter-
mediate care unit during the twins’ stay showed that 3 were 
colonized. In addition, rectal screening of 31 HCWs indi-
cated that 2 (7%) were positive for ESBL E. coli. Invasive 
infection did not develop in any of the 3 neonates colonized 
with ESBL E. coli.
Monthly follow-up screening was performed for the 2 
HCWs who were positive for ESBL E. coli. They contin-
ued working after reeducation about general hygiene pre-
cautions. One HCW left her job at the hospital and was lost 
to follow-up; the other was negative for ESBL E. coli at 
2-month follow-up.
Rectal swab specimens for surveillance of intestinal 
carriage were obtained from all patients in the neonatal in-
termediate care unit during the outbreak and at 2 weeks, 
5 months, and 7 months after the outbreak. Screening for 
ESBL E. coli carriage among HCWs was performed by ob-
taining rectal swabs.
Cultures were performed by using CHROMagar ori-
entation  medium  (Becton  Dickinson  BBL  Diagnostics, 
Sparks, MD, USA). ESBL production was identified ac-
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cording to the guidelines of the Clinical Laboratory Stan-
dards  Institute  (12).  Routine  susceptibility  testing  was 
performed by microbroth dilution (Micronaut-S; Merlin, 
Bornheim-Hersel,  Germany).  Four  cephalosporins  (cef-
podoxime, ceftriaxone, ceftazidime, and aztreonam) were 
used  for  screening.  If >1  of  the  cephalosporins showed 
increased MICs, ESBL E. coli was confirmed with Etest 
strips (AB Biodisk, Solna, Sweden) containing cefotaxime 
or ceftazidime, each with and without clavulanic acid.
Molecular typing was performed by pulsed-field gel 
electrophoresis (PFGE). ESBL was molecularly confirmed 
by PCR amplifying genes for TEM, SHV, and CTX-M 
β-lactamases. Amplicons were sequenced by using an ABI 
3130 Genetic Analyzer (Applied Biosystems, Foster City, 
CA, USA).
Genotyping by PFGE showed 1 dominant ESBL E. 
coli strain; 2 different genotypes were found in 1 HCW and 
in 1 of the screened neonates staying in the same unit as 
the twins (Figure 1). The outbreak strain was found in the 
index patient, her twins, 2 neonates staying in the neona-
tal intermediate care unit at the same time, and 1 HCW   
(Figure 2). Sequencing of the ESBL gene showed TEM-29 
type. Surveillance cultures performed on all patients in the 
neonatal intermediate care unit indicated no further ESBL 
E. coli was present at 2 weeks, 5 months, and 7 months 
after the outbreak.
Before the outbreak, a quaternary ammonium–based 
disinfectant was used daily to clean the neonatal unit. HCWs 
routinely cared for healthy babies without using gloves but 
did use an alcohol-based hand sanitizer. Products for pa-
tient care were shared among neonates; in particular, no 
protective covering was used for clinical thermometers.
After  screening  showed  ESBL  E.  coli,  reinforced 
infection control strategies were established. A schedule 
of  training  sessions  emphasizing  proper  hand  hygiene, 
routine use of protective covering for clinical thermom-
eters,  environmental  cleaning  using  an  aldehyde-based 
disinfectant, and routine use of gloves and gowns for any 
patient contact (particularly changing diapers) was insti-
tuted. Furthermore, separate care products were used for 
each neonate.
Conclusions
We report an outbreak caused by transmission of ESBL 
E. coli from a mother to her newborn twins and subsequent 
spread to other neonates and 1 HCW. The mother was most 
likely colonized before hospitalization, and a urinary tract 
infection developed peripartum. Transmission by contact 
during vaginal delivery of the twins and transmission by 
physical contact to 1 of the HCWs and the other neonates 
was the most likely mode of transmission. We interpret the 
detection of ESBL E. coli infection in 1 of the neonates and 
the other HCW as a coincidence because both had a differ-
ent genotype (TEM-12) and PFGE pattern type of ESBL 
E. coli.
Because we screened only for ESBL E. coli, we might 
have underestimated the true extent of the outbreak. How-
ever,  the  ESBL-encoding  gene,  which  is  on  a  plasmid, 
could  have  been  transferred  to  other  Enterobacteraceae 
and would have been missed. Risk factors for coloniza-
tion  in  newborns  include  low  birthweight,  duration  of 
hospitalization, total parenteral nutrition, previous use of 
antimicrobial drugs, and mechanical ventilation in a neo-
natal ICU (13). In the intermediate care setting, breastfeed-
ing was associated with a lower risk for ESBL-producing 
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Figure 1. Molecular typing of extended-spectrum β-lactamase–producing Escherichia coli isolates by pulsed-field gel electrophoresis. 
Dendrogram shows a cluster of 6 isolates with identical banding pattern and 2 isolates with 2 distinct patterns.
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Figure  2.  Spread  of  extended-spectrum  β-lactamase–producing 
Escherichia coli outbreak. NICU, neonatal intensive care unit.Enterobacteriaceae (14) because breastfed neonates have 
more contact with their mothers and therefore are possibly 
less frequently handled by HCWs. Our patients had only 1 
identified risk factor: the twins from the colonized mother 
had low birthweight; the other neonates had no risk factors. 
Improved infection control strategies may be necessary to 
limit spread of ESBL E. coli in maternity wards because 
transmission to neonates during delivery is possible. A fea-
sible approach could be to screen mothers whose neonates 
need to be transferred to ICUs; an outbreak in this setting 
would be particularly harmful. 
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